Chicago Ridge, ILNCT06919965Now EnrollingIRB Ready

Non-Muscle Invasive Bladder Neoplasms Clinical Trial in Chicago Ridge, IL

Access cutting-edge non-muscle invasive bladder neoplasms treatment through this clinical trial at a research site in Chicago Ridge. Study-provided care at no cost to qualified participants.

Sponsored by Janssen Research & Development, LLC

Quick Self-Assessment

See if you qualify for this Chicago Ridge location

Preparing your pre-screening questions…

Expert Care in Chicago Ridge

Access non-muscle invasive bladder neoplasms specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related non-muscle invasive bladder neoplasms treatment provided free

Apply for This Chicago Ridge Location

Check if you qualify for this non-muscle invasive bladder neoplasms clinical trial in Chicago Ridge, IL

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Chicago Ridge

    Convenient for IL residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Chicago Ridge site if eligible
  4. 4Begin participation

About This Non-Muscle Invasive Bladder Neoplasms Study in Chicago Ridge

The main purpose of this study is to compare the disease-free survival (the length of time after randomization that a participant survives without any signs or symptoms of the cancer returning, or progressing) between Bacillus Calmette-Guérin (BCG) treated participants receiving treatment with TAR-210 versus investigator's choice of intravesical chemotherapy for treatment of high-risk non-muscle-invasive bladder cancer (HR-NMIBC).

Sponsor: Janssen Research & Development, LLC

Who Can Participate

Inclusion Criteria

Histologically confirmed diagnosis by local pathology of papillary-only HR-NMIBC (defined as high-grade Ta or any T1, no CIS). Mixed histology tumors are allowed if urothelial differentiation is predominant. However, neuroendocrine, and small cell variants will be excluded
Have a susceptible fibroblast growth factor receptor (FGFR) mutation or fusion either by urine testing or tumor tissue testing (from TURBT tissue) as determined by central or local testing
All visible tumor completely resected prior to randomization. Urine cytology must not be positive or suspicious for high grade UC before randomization. For participants with lamina propria invasion (T1) on the screening biopsy/TURBT, muscularis propria must be present to rule out MIBC
Participants must have had either: a. Adequate Induction (5 of 6 doses) and either 2 of 3 doses of Maintenance or 2 of 6 doses of second Induction of BCG with high-grade T1 disease at first disease assessment after induction or high-grade Ta/any T1 disease within 6 months after last BCG (BCG-unresponsive population); b. had adequate induction (5 or 6 doses) with or without maintenance BCG with high-grade Ta/any T1 disease within 12 months after last BCG excluding BCG-unresponsive (BCG-experienced population); or c. been unable to complete an induction course of BCG with at least 5 doses due to grade \>= 2 toxicity requiring BCG discontinuation (BCG intolerant population)
Have an Eastern Cooperative Oncology Group (ECOG) performance status Grade of 0, 1, or 2
Must be ineligible for or refusing radical cystectomy (RC)

Exclusion Criteria

Presence of CIS at any point from time of diagnosis of papillary-only HR-NMIBC recurrence to randomization. Additionally, presence or history of histologically confirmed, muscle-invasive, locally advanced, nonresectable, or metastatic urothelial carcinoma (that is \[i.e.\], T2, T3, T4, N+, and/or M+)
Active malignancies (i.e., progressing or requiring treatment change in the last 24 months) other than the disease being treated under study. Allowed recent second or prior malignancies: a. Any malignancy that was not progressing nor requiring treatment change in the last 12 months; b. Malignancies treated within the last 12 months and considered at very low risk for recurrence for example (e.g.): non-melanoma skin cancers (treated with curative therapy or localized melanoma treated with curative surgical resection alone), non-invasive cervical cancer, breast cancer (adequately treated lobular CIS or ductal CIS, localized breast cancer and receiving antihormonal agents), localized prostate cancer (\[N0, M0\] with a Gleason score less than or equal to \[\<=\] 7a, treated locally only \[radical prostatectomy/radiation therapy/focal treatment\]) and other malignancy that is considered at minimal risk of recurrence
Presence of any bladder or urethral anatomic feature that, in the opinion of the investigator, may prevent the safe placement, indwelling use, or removal of TAR 210
A history of clinically significant polyuria with recorded 24 hour urine volumes greater than (\>) 4,000 milliliters (mL)
Indwelling catheters are not permitted; however, intermittent catheterization is acceptable

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Chicago Ridge?

Yes, this clinical trial (NCT06919965) has an active research site in Chicago Ridge, IL that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Non-Muscle Invasive Bladder Neoplasms Treatment Options in Chicago Ridge, IL

If you're searching for non-muscle invasive bladder neoplasms treatment options in Chicago Ridge, IL, this clinical trial (NCT06919965) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Chicago Ridge research site is actively enrolling participants for this clinical trial. You'll receive care from experienced non-muscle invasive bladder neoplasms specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all non-muscle invasive bladder neoplasms clinical trials near you to find additional studies recruiting in your area.

More Alzheimers Disease Trials in Chicago Ridge, IL

See all alzheimers disease clinical trials recruiting in Chicago Ridge — not just this study.

Browse Alzheimers Disease Trials in Chicago Ridge →

Browse More Trials by Condition

Alzheimers Disease TrialsMultiple Sclerosis TrialsADHD TrialsAnkylosing Spondylitis TrialsAtopic Dermatitis TrialsAll Conditions →

Ready to Join in Chicago Ridge?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Chicago Ridge, IL